Buccal absorption is one of the most efficient and medically effective drug-delivery systems available today. TruMedica Strips deliver active ingredients through the highly vascularized tissue inside the cheek and roof of the mouth — bypassing the digestive tract entirely and avoiding hepatic first-pass metabolism. The result is rapid onset, higher bioavailability, and predictable blood levels.

Unlike troches, lozenges, and oral capsules that must pass through the digestive system — causing enzyme degradation, inconsistent absorption (often only 5–20%), and common GI side effects — buccal strips avoid all of that. There's no saliva dilution, no messy crumble or melt, and no 20–30 minute dissolve time. Strips dissolve within minutes with 99%+ dissolution, delivering the fastest and most efficient drug delivery outside of IV therapy without needles, pain, or medical oversight.

The underlying science relies on nanocrystal dispersion that dramatically increases surface area for absorption, mucoadhesive polymer technology that ensures consistent absorption, and precision-dosed micro-layering that guarantees accurate delivery every time. TruMedica strips can carry sub-10mg to 500+mg capacity, accommodating virtually any formula. Every strip is individually foil-packaged, room-temperature stable, and travel-friendly.

TruMedica commissioned a randomized, double-blind comparison study evaluating its patent-pending TruRelease™ absorption technology in oral thin film (buccal strip) delivering reduced glutathione. The study enrolled 20 subjects split into two groups of 10, each receiving a different strip formulation. All subjects were baselined over 4 weeks prior to dosing. On dosing day, subjects fasted and had serial whole-blood glutathione levels drawn at 0, 10, 30, 60, 120, and 240 minutes post-administration.

Both formulations demonstrated that glutathione — and by extension other peptides — can be effectively absorbed through the oral mucosa, achieving 91-93% absorption rates. The critical difference: TruRelease™ (Strip A), which includes proprietary penetration enhancers, reached peak blood concentration (Tmax) at just 23 minutes, versus 59 minutes for the control strip (Strip B). That's roughly 2x faster speed to onset, validating buccal strip delivery as the fastest and most efficient drug delivery outside of IV therapy.

In a landscape saturated with unverified "361" tissue products, DynaCord™ stands apart. DynaCord has successfully secured FDA Investigational New Drug (IND) clearance under the rigorous Section 351(a) biologics pathway — making it the only 351(a)-classified exosome product in the world. This represents a fundamental shift from "tissue" to "drug," meeting strict standards for safety, purity, and potency that 361 tissue products cannot.

The FDA has repeatedly stated that exosomes are 351(a) Biological Drugs, not simple tissues. "IND Cleared" is not a marketing term — it is a validation of transparency and safety data. The FDA holds DynaCord's Master File (DMF) containing proprietary Chemistry, Manufacturing, and Controls (CMC) data. Pre-clinical safety data has been reviewed and accepted by FDA pharmacologists, a hurdle most tissue products cannot clear.

DynaCord exosomes are derived from Wharton's Jelly-derived human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) — offering a youthful biological profile that avoids the cellular aging and senescence of adult donors, high proliferative capacity essential for manufacturing reproducible therapeutics, and what is widely considered the most potent source for regenerative signaling molecules.

Exosomes are small, extracellular vesicles generated through endocytosis that play a crucial role in intercellular communication. They act as messengers, transporting bioactive cargo — mRNA, miRNA, cytokines, growth factors, and structural proteins — from donor cells to recipient cells, where the cargo modulates gene expression and signaling pathways, coordinating activities like immune response and tissue repair. Because DynaCord's exosomes are derived from hUC-MSCs, the cargo is inherently more bioactive than that of older tissue sources.

The FDA has consistently stated that exosome products are 351(a) Biological Drugs, not simple tissues. Per 21 CFR Part 1271, any HCT/P that fails to meet ALL 361 criteria — minimal manipulation, homologous use, no combination, no systemic effect — requires a Biologics License Application under 351(a). Exosome preparations are, by definition, more than minimally manipulated and are used systemically. There is no legitimate 361 pathway for exosome therapy.

RejuvXO is the first-ever device and exosome regenerative serum combination system with in-device exosome application. The patent-pending device uses precision-engineered micro-channel vibration, microdermabrasion, and dual-wavelength light (blue + red) to open the skin barrier and enhance high-grade topical absorption of exosomes, growth factors, peptides, PRP, and PDRN — all without needles, numbing, or downtime. The skin barrier seals in just 15 minutes post-use.

Each 3mL pre-filled cartridge contains 10 billion exosomes, and cartridges ship in cases of 20 (200 billion exosomes per case). Results are typical in 4-6 weeks. The exosomes are shelf-stable at room temperature for 18 months, and every shipment includes a COA with manufacturer-direct support. The exosome skincare market is estimated at $423 million (2024), growing to $796 million by 2031 with a CAGR of 9.6% — positioning your practice at the frontier of regenerative aesthetics.